A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin

American Journal of Reproductive Immunology

Volumn 35, Issue 4, 1996, Pages 402-407

  Kutteh, William H ^a   Ermel, Leann D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antiphospholipid antibodies; Heparin; Low dose aspirin; Recurrent pregnancy loss

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PHOSPHOLIPID ANTIBODY;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; PREGNANCY; PRIORITY JOURNAL; RECURRENT ABORTION; SPONTANEOUS ABORTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029970670     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1996.tb00501.x     Document Type: Conference Paper

References (24)

1. Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989; 20:52-67.
2. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/ antithrombin III cofactor activity by anticardiolipin antibodies: A mechanism for thrombosis. Thromb Res 1993; 71:103-111.
3. Shibata S, Harpel P, Bona C, Filit H. Monoclonal antibodies to heparin sulfate inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 1993; 67:264-272.
4. Rote NS. Pregnancy-associated immunological disorders. Curr Opin Immunol 1989; 1:1165-1172.
5. Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74:1-9.
6. Kutteh WH, Pasquarette M. Recurrent pregnancy loss. In Advances in Obstetrics and Gynecology. Rock, JA (ed). Mosby-Yearbook, Inc., St. Louis, 1995, Vol 2, pp 147-177.
7. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 155:1318-1323.
8. Kutteh WH, Wester RM. A prospective controlled trial of aspirin alone (ASA) versus heparin (Hep) plus aspirin for the treatment of recurrent pregnancy loss associated with antiphospholipid antibodies (APA). American Fertility Society, 49th Annual Meeting, Montreal, Quebec, Canada 1993; 0-142:568.
9. Rosove MH, Tabsh K, Wasserstrum N, Howard P, Hahn BH, Kalunian KC: Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990; 75:630-634.
10. Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33:14-20.
11. 2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb Res 1992; 68:495-500.
12. McIntyre JA, Taylor CG, Torry DS, Wagenknecht DR, Wilson J, Faulk WP. Heparin and pregnancy in women with a history of repeated miscarriages. Haemostasis 1993; 23(suppl 1):202-211.
13. Kutteh WH, Wester RM. Multiples of the median: An alternate method for reporting antiphospholipid antibodies in women with recurrent pregnancy loss. Obstet Gynecol 1994; 84:811-815.
14. Griffith GC, Nichols G, Asher JD, et al. Heparin osteoporosis. JAMA 1965; 193:85-88.
15. Dahlman T, Lindvall N, Hellgren M: Osteopenia in pregnancy during long-term heparin treatment: A radiologic study postpartum. Br J Obstet Gynecol 1990; 97:221-228.
16. Branch DW, Rote NS, Dostal DA, Scott JR. Association of lupus anticoagulant with antibody against phosphatidylserine. Clin Immunol Immunopathol 1987; 42:63-75.
17. Rote NS, Dostal-Johnson DA, Branch DW. Antiphospholipid antibodies and recurrent pregnancy loss: Correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol 1990; 163:575-584.
18. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160:439-43.
19. Coulam CB, Stern JJ, Bustillo M. Ultrasonographic findings of pregnancy losses after treatment for recurrent pregnancy loss: Intravenous immunoglobulin versus placebo. Fertil Steril 1994; 61:248-251.
20. Branch DW, Silver RM, Blackwell JC, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614-620.
21. Laros RK. Thromboembolic disorders. In Maternal Fetal Medicine, 3rd edition. Creasy RK, Resnick R (eds). WB Saunders Co., Philadelphia, 1994, Vol 48, pp 792-803.
22. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22:359-374.
23. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipid antibodies: An historical cohort. Obstet Gynecol 1994; 83: 372-377.
24. Laufer MR, Ecker JC, Hill JA. Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions. J Soc Gynecol Invest 1994; 1:138-142.